Last update 08 May 2025

Olanzapine/Zonisamide

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Olanzapine/zonisamide SR, Zonisamide SR/olanzapine, Zonisamide/olanzapine
+ [1]
Target
5-HT2 receptor x CAs x D1 receptor x D2 receptor x SCNA x VDCCs
Action
antagonists, inhibitors, blockers
Mechanism
5-HT2 receptor antagonists(Serotonin 2 (5-HT2) receptor antagonists), CAs inhibitors(Carbonic anhydrases inhibitors), D1 receptor antagonists(Dopamine D1 receptor antagonists)
+ [3]
Therapeutic Areas
Endocrinology and Metabolic DiseaseOther Diseases
Active Indication-
Inactive Indication
ObesitySchizoaffective disorderSchizophrenia+ [1]
Originator Organization
Orexigen Therapeutics, Inc.Orexigen Therapeutics, Inc.
Active Organization-
Inactive Organization
Orexigen Therapeutics, Inc.Orexigen Therapeutics, Inc.
License Organization-
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC17H20N4S
InChIKeyKVWDHTXUZHCGIO-UHFFFAOYSA-N
CAS Registry132539-06-1
View All Structures (2)

Related

1
Clinical Trials associated with Olanzapine/Zonisamide
NCT00734435
/ TerminatedPhase 2
A Proof of Concept, Multi-Center, Randomized, Double-Blind, Parallel, Placebo-Controlled, Study of Zonisamide Sustained Release (SR) 360 mg Versus Placebo in the Prevention of Weight Gain Associated With Olanzapine Therapy for Psychosis
100 Clinical Results associated with Olanzapine/Zonisamide
Login to view more data
100 Translational Medicine associated with Olanzapine/Zonisamide
Login to view more data
100 Patents (Medical) associated with Olanzapine/Zonisamide
Login to view more data
100 Deals associated with Olanzapine/Zonisamide
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Schizoaffective disorderPhase 2
United States
Orexigen Therapeutics, Inc.Orexigen Therapeutics, Inc.
01 Sep 2008
SchizophreniaPhase 2
United States
Orexigen Therapeutics, Inc.Orexigen Therapeutics, Inc.
01 Sep 2008
Weight GainPhase 2
United States
Orexigen Therapeutics, Inc.Orexigen Therapeutics, Inc.
01 Sep 2008
ObesityPhase 2
United States
Orexigen Therapeutics, Inc.Orexigen Therapeutics, Inc.
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free